Led · Seed · Apr 2026

Carbonyx commercializes a process developed at the University of British Columbia that treats waste rock and other industrial wastes to recover valuable materials such as carbonates and silica while enhancing the materials' natural ability to capture CO2 via electrically induced reactions with water. The company was born in UBC’s Curtis P. Berlinguette Research Group and is led by co-founder and CEO Doug Pimlott, with Berlinguette as co-founder and advisor and a team that includes head of engineering Adrien Noble and PhD chemist Mia Stankovic. Carbonyx is building a shipping-container-sized demonstration unit intended to move production from kilograms per year to multi-tonnes, with an anticipated commercial-scale-like deployment in two to three years and a goal of megatonne-scale extraction within 10 years. The startup plans to broaden its recovered- materials portfolio over time to include critical minerals and rare earth elements while generating revenue from the materials it sells to make carbon removal economically viable.

Participated · Seed · Apr 2026

ViewsML develops an AI-driven virtual biomarker staining platform that virtualizes immunohistochemistry to deliver per-cell spatial biomarker insights from standard H&E slides. The platform is intended to preserve scarce tissue samples while accelerating research, clinical trials, and patient care. ViewsML is building a virtual biomarker library comprised of AI models that extract biomarker information directly from routine pathology images. The company has established strategic collaborations with healthcare institutions, diagnostic companies, and biopharma organizations to drive adoption across research and clinical applications. Led by CEO Kenneth To, ViewsML plans to use newly raised seed capital to commercialize the platform, expand partnerships, advance clinical validation of its virtual biomarker panels, and grow its engineering, scientific, and commercial teams.

Led · Seed · Nov 2025

CereCura Nanotherapeutics is a Vancouver-based spin-out from the University of British Columbia that uses lipid nanoparticle–ribonucleic acid (LNP-RNA) technology—first popularized in COVID-19 vaccines—to ferry genetic instructions into the brain. Its lead candidate targets neuronopathic Gaucher disease by supplying mRNA for the missing enzyme glucocerebrosidase, and the same platform is being advanced for Alzheimer’s and Parkinson’s indications. In pre-clinical studies the company has successfully delivered multiple proteins to rodent brains with a week-long half-life, overcoming the blood-brain barrier that limits conventional enzyme replacement therapies. The science is guided by LNP pioneer and co-founder Pieter Cullis alongside CEO and neuroscientist Louis-Philippe Bernier. Management intends to build a pipeline of pre-clinically validated assets that can move quickly toward clinical development. CereCura has raised C$2.2 million in equity financing to date and secured more than C$4 million in government grants, funding upcoming efficacy work in rodents and larger animals.

Participated · Seed · Dec 2023

Inverted AI develops predictive human behavioral models learned from large quantities of video data and transfers those models into simulated environments to drive realistic, diverse, and reactive NPCs for ADAS and AV testing. Its ITRA (Imagining the Road Ahead) technology enables longer, more complex simulation scenarios to test systems against a full range of human road-user behaviors. The company offers API access to DRIVE (human-like NPC driving behaviors) and INITIALIZE (realistic agent placements), and is beta testing BLAME (automatic collision attribution) and SCENARIO (whole-scene scenario generation). Inverted AI says its technology reduces development costs and time by enabling diverse, realistic testing scenarios for ADAS, autonomous vehicles, and robots. The company recently launched a new site with an interactive demo and trial API key sign-up. In December 2023 it raised over $4M in seed funding to accelerate and expand its product offerings based on ITRA; the business is led by CEO Frank Wood and is based in Vancouver, BC, Canada.

Participated · Equity · Jun 2022

Care2Talk is a Victoria-based health‑tech communications company that provides a simple-to-use cloud platform for seniors in care homes to improve access to caregivers and loved ones. Founder and CEO Jordan Schley created the product after observing isolation at his grandfather’s assisted living facility and finding traditional communications solutions too complex. The company has gained early adoption with assisted living facilities across the country and is building partnerships with doctors and medical groups to expand telehealth services. Care2Talk reported rapid usage growth and plans to launch Care2Talk Health, a telehealth platform fully dedicated to senior care. In June 2022 it completed a $1 million fundraise from a group of Canadian investors. Sprout Fund said it will invest and help grow the company, bringing seed-stage capital and mentorship.